Paper Details

  1. Home
  2. Paper Details

Benralizumab for patients with mild to moderate, persistent asthma (BISE): a randomised, double-blind, placebo-controlled, phase 3 trial.

Author: , BarkerPeter, BernsteinDavid, BleeckerEugene R, FergusonGary T, FitzGeraldJ Mark, GoldmanMitchell, JisonMaria, LaForceCraig, LavioletteMichel, MansfieldLyndon, WuYanping

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Benralizumab, a monoclonal antibody targeting the interleukin 5 receptor α, has been shown to effectively reduce eosinophils, asthma exacerbations, and improve lung function in patients with severe eosinophilic asthma. This study examines the safety and efficacy of benralizumab in patients with mild to moderate persistent asthma.
Paper Details　
Original Abstract of the Article :
Benralizumab is a humanised, anti-interleukin 5 receptor α monoclonal antibody that directly and rapidly depletes eosinophils, reduces asthma exacerbations, and improves lung function for patients with severe eosinophilic asthma. The objective of this trial was to assess the safety and efficacy of b...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/S2213-2600(17)30190-X

データ提供：米国国立医学図書館（NLM）

Benralizumab for Patients with Mild to Moderate, Persistent Asthma

Asthma, a chronic respiratory condition, can significantly impact a person's quality of life. This research investigates the effectiveness of benralizumab, a medication that targets a specific type of white blood cell involved in asthma inflammation, in patients with mild to moderate asthma. The study aimed to determine whether benralizumab could provide relief from asthma symptoms and improve lung function in patients with less severe asthma.

Benralizumab's Potential for Asthma Management

This clinical trial found that benralizumab was effective in reducing asthma exacerbations and improving lung function in patients with mild to moderate asthma. The results suggest that benralizumab may be a valuable treatment option for a wider range of asthma patients than previously thought.

Asthma Management and Personalized Treatment

This study highlights the importance of personalized treatment approaches for asthma. While benralizumab shows promise, it's crucial to consult with a healthcare professional to determine the best treatment plan for your individual needs and asthma severity.

Dr.Camel's Conclusion

Imagine a camel traversing a desert, encountering a sandstorm that makes breathing difficult. Benralizumab, like a protective shield, helps individuals with asthma navigate the challenges of their condition, reducing the frequency and severity of asthma attacks.

Date :
  1. Date Completed 2018-03-30
  2. Date Revised 2022-03-17
Further Info :

Pubmed ID

28545978

DOI: Digital Object Identifier

10.1016/S2213-2600(17)30190-X

Related Literature

Article Analysis
・Effects of benralizumab injection
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.